Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update Contents: Agreement Readies Denmark, Austria for Approval of Vertex CF Therapies CF Treatments Made Me Deaf, but Sound Is More Beautiful Than Ever Before Decibel Obtains Exclusive License for ORC-13661 for Prevention of Antibiotic-related Ototoxicity Agreement Readies Denmark, Austria for Approval of Vertex CF Therapies Oct 03, 2018 07:00 am | Diogo Pinto Vertex Pharmaceuticals has entered a partnership with the Danish pharmaceutical organization Amgros to one day make Vertex’s cystic fibrosis (CF) therapies available for Danish patients. The collaboration was made through an access contract, a first-of-its-kind contract that gives Danish CF patients access to all Vertex’s current and future CF drugs after their regulatory approval. The contract was […] The post Agreement Readies Denmark, Austria for Approval of Vertex CF Therapies appeared first on Cystic Fibrosis News Today. Read More CF Treatments Made Me Deaf, but Sound Is More Beautiful Than Ever Before Oct 02, 2018 09:00 am | Brad Dell Fall 2010 I’ll never forget the morning I couldn’t understand what my friends said as we waited for classes to begin. I’ll never forget calling Mom, phone pressed to my right ear, and not understanding what she said, either. Or my heaving sobs as friends looked on. Or Mom texting me many minutes later to […] The post CF Treatments Made Me Deaf, but Sound Is More Beautiful Than Ever Beforeappeared first on Cystic Fibrosis News Today. Read More Decibel Obtains Exclusive License for ORC-13661 for Prevention of Antibiotic-related Ototoxicity Oct 02, 2018 07:30 am | Diogo Pinto Decibel Therapeutics received worldwide, exclusive rights to develop and commercialize ORC-13661, Oricula Therapeutics’ investigational treatment to prevent hearing loss and balance disorders in patients taking high doses of aminoglycoside antibiotics, including cystic fibrosis (CF) patients. Under the terms of the agreement, Oricula will provide scientific advice and support to Decibel throughout the ORC-13661 development process. […] The post Decibel Obtains Exclusive License for ORC-13661 for Prevention of Antibiotic-related Ototoxicity appeared first on Cystic Fibrosis News Today. Read More   Recent News Is It Our Responsibility to Educate Others About CF? MS1819-SD Shows Positive Results for Exocrine Pancreatic Insufficiency in Phase 2a Trial In Memory of Serena Lawrence, Who Inspired Voices of the Hurting and Sick #NACFC — Sound Pharmaceuticals to Present Preliminary Data on Ototoxicity Study Vivus Lends Support to CFF Dallas, Forth Worth Chapters’ Recent CF Climb Fundraiser